Carlos Alberto Corona-Arias

Dr. Carlos Alberto Corona-Arias

Cardiovascular Surgery, Fundación Cardiovascular de Colombia, Floridablanca, Colombia
orcid
Universidad Industrial de Santander

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SGSergio Alejandro Gomez-Ochoa
Sergio Alejandro Gomez-Ochoa
LRLyda Z. Rojas
Lyda Z. Rojas
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
LQLizeth N. Quiroga-Pico
Lizeth N. Quiroga-Pico
LALaura Valentina Arciniegas-Landinez
Laura Valentina Arciniegas-Landinez
LELuis Echeverria
Luis Echeverria
Background/Objectives: Contemporary heart failure (HF) guidelines recommend early initiation of four foundational drug classes in HFrEF. However, real-world prescription rates of guideline-directed medical therapy (GDMT) at discharge remain low, and comparative data in this setting is limited. We aimed to explore the association between GDMT intensity prescribed at or before hospital discharge and clinical outcomes. Methods: MEDLINE and EMBASE were searched through March 2026 (PROSPERO CRD420261352137). A frequentist random-effects network meta-analysis grouped regimens into four intensity nodes (single/none, double, triple, quadruple), with the primary analysis restricted to adjusted hazard ratios. The primary outcome was the composite of all-cause mortality (ACM) and HF hospitalization (HFH). Secondary outcomes were HFH alone, ACM, and cardiovascular mortality. Confidence was rated with CINeMA. Estimates are reported as associations, not treatment effects. Results: Twenty-seven studies (26 observational, 1 RCT; 73,174 patients) were included. Among SGLT2i-era cohorts, quadruple therapy was suboptimally prescribed (pooled 34%, range 11.6–55.2%). For the primary composite endpoint, more complete regimens were associated with progressively lower event rates versus single or no therapy (double: hazard ratio 0.76, 95% CI 0.68–0.84; triple: 0.72, 0.64–0.81; quadruple: 0.52, 0.36–0.75; τ2 = 0). A consistent ordinal gradient was seen across outcomes, with quadruple therapy ranking first numerically for every outcome in which it was estimable. The direction and ordering were preserved in a sensitivity analysis additionally incorporating risk ratios, on stratification by follow-up duration, and in an alternative network anchored to incomplete therapy. Because most evidence was observational, the magnitude of these associations should not be interpreted as a causal treatment effect and likely reflects residual confounding and selection bias. Conclusions: Discharge GDMT remains an important opportunity to improve outcomes in patients with HF. Adequately powered randomized trials are required to establish the incremental benefit of this approach and to close the gap between evidence and practice.

1 July 2025 in SAGA: Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
RGRicardo Daniel Corona González
Ricardo Daniel Corona González
ASAmy Scarlet Martínez Salto
Amy Scarlet Martínez Salto
MYManuel Maximiliano Paredes Ydiaquez
Manuel Maximiliano Paredes Ydiaquez
RTRichard Adrian Vergara Trujillo
Richard Adrian Vergara Trujillo
EEErwin Giovanny Mercado Estrada
Erwin Giovanny Mercado Estrada
Medicine shortages have emerged as a persistent global health challenge, affecting both high-income and low- and middle-income countries. This study analyzed the prevalence, duration, recurrence, systemic drivers, and coping strategies associated with shortages in Mexico, Colombia, and Peru, situating the findings within the international context. Using a cross-sectional design with 1,250 participants, results revealed that shortages were most frequent among antimicrobials, oncology agents, insulin, and anesthetics. These shortages not only lasted longer and recurred more often than in other therapeutic categories but also disproportionately affected low-income and rural populations. Coping strategies included therapeutic substitution and private purchasing, but also riskier responses such as resorting to informal markets and treatment abandonment. Participants identified manufacturing failures, import dependence, and procurement weaknesses as the main systemic drivers, consistent with international evidence. The findings highlight that medicine shortages are not isolated events but structural failures embedded within fragile pharmaceutical systems. Addressing them requires proactive, resilient, and equity-focused policies, including early warning systems, resilient procurement models, diversification of supply chains, and targeted protections for vulnerable populations.

1 July 2025 in SAGA: Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
JEJorge Angel Velasco Espinal
Jorge Angel Velasco Espinal
JRJuan Francisco Molina Rodríguez
Juan Francisco Molina Rodríguez
IHIngrid Monserrat Jaimes Hernández
Ingrid Monserrat Jaimes Hernández
SSSebastian Guardiola Segovia
Sebastian Guardiola Segovia
CVClaudia Patricia Mieles Velázquez
Claudia Patricia Mieles Velázquez
RGRicardo Daniel Corona González
Ricardo Daniel Corona González
This study analyzed how social determinants of health influence equity in healthcare access across Mexico, Colombia, and Ecuador. A total of 3,600 adults participated, representing diverse sociodemographic profiles by age, gender, education, income, and ethnicity. A cross-sectional, comparative design was employed, using a harmonized survey instrument and semi-structured interviews to examine insurance coverage, healthcare utilization, barriers to access, discrimination, and perceptions of equity. Descriptive and inferential analyses showed that uninsured status, low income, limited education, rural residence, and indigenous identity were the strongest predictors of inequitable access. Colombia exhibited higher levels of public insurance coverage, more frequent healthcare utilization, and greater trust in institutions, while Mexico and Ecuador displayed larger uninsured populations, more pronounced economic and geographic barriers, and higher reports of discrimination. Participants in Ecuador reported the poorest self-rated health, whereas Colombia showed the most favorable assessments. Across all three countries, public insurance schemes played a central role in coverage, but systemic barriers such as long waiting times, medicine shortages, and service saturation continued to limit effective access. The findings confirm that inequities in healthcare access are shaped by both structural and cultural determinants, reinforcing the need for policies that extend beyond insurance reform to address poverty, education, ethnicity, and geographic disparities. These results contribute to regional debates on universal health coverage and highlight the importance of designing strategies that strengthen equity in health systems throughout Latin America.

1 January 2026 in Brazilian Journal of Psychiatry
Verified
Journal Article
Closed access
JCJoan Utria Castro
Joan Utria Castro
MAMary Cielo Arias Asprilla
Mary Cielo Arias Asprilla
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
PBPaula Andrea Lubo Brito
Paula Andrea Lubo Brito
KCKaren Tatiana Rodríguez Cardozo
Karen Tatiana Rodríguez Cardozo
MEMaría Camila Madariaga Estupiñán
María Camila Madariaga Estupiñán
Haloperidol is widely used for agitation, psychosis, and delirium, but concerns remain regarding QTc prolongation and ventricular arrhythmias. We evaluated the association between haloperidol and QTc prolongation in adults with psychiatric or behavioral indications and secondarily summarized clinically relevant proarrhythmic events. We conducted a systematic review registered in PROSPERO (CRD420261306215) following PRISMA 2020. Randomized controlled trials and comparative observational studies enrolling adults receiving haloperidol versus placebo, no antipsychotic, or another antipsychotic were included. The primary outcome was QTc prolongation as defined by study authors. A sensitivity analysis assessed QTc ≥500 ms when explicitly reported by study arm. Meta-analyses were performed using odds ratios when appropriate. Risk of bias was assessed with RoB 2 and the Newcastle-Ottawa Scale; certainty was rated with GRADE. Sixteen unique studies (17 publications; 16,189 participants) were included. In placebo- or no-antipsychotic comparisons (k=3 randomized controlled trials), haloperidol was not associated with a clear difference in QTc prolongation by author-defined thresholds (random-effects OR=1.18, 95%CI 0.83-1.69; I²=0%). In the sensitivity analysis restricted to QTc ≥500 ms (k=2 randomized controlled trials), evidence was imprecise due to the small number of studies, low event frequency, and wide confidence interval (OR=1.00, 95%CI 0.38-2.65). Clinically relevant proarrhythmic events were infrequent and usually not reported by study arm or yielded double-zero data, precluding quantitative synthesis. : In placebo-controlled trials conducted in intensive care settings, haloperidol did not show an increase in QTc prolongation by author-defined criteria. Evidence for QTc ≥500 ms remains limited by imprecision, and clinically relevant proarrhythmic events were rare and inconsistently reported.

9 February 2026 in Arandu UTIC
Verified
Journal Article
Open access
PDF file
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
DADanna Isabella Hernandez Abreo
Danna Isabella Hernandez Abreo
LMLia Carolina Payares Meza
Lia Carolina Payares Meza
APAndrés Felipe Sierra Peña
Andrés Felipe Sierra Peña
CLCarlos Alfonso Diaz Lizarraga
Carlos Alfonso Diaz Lizarraga
La insuficiencia cardíaca avanzada es un síndrome terminal caracterizado por disfunción ventricular severa y compromiso multiorgánico, incluido el sistema urológico. Realizamos una revisión sistemática de estudios observacionales y ensayos clínicos que evaluaron complicaciones urológicas en la insuficiencia cardíaca avanzada, siguiendo las directrices del Cochrane Handbook. Cinco estudios, con un total de 1,478 participantes, cumplieron los criterios de elegibilidad. Los desenlaces primarios fueron la prevalencia y el impacto en la calidad de vida, evaluados mediante instrumentos validados (RAND-36, IIQ-SF7). La disfunción sexual fue altamente prevalente, reportada en el 48–84% de los hombres y el 63–80% de las mujeres, y se asoció con mayor edad, obesidad y baja actividad física. La incontinencia urinaria afectó al 49% de los pacientes y se relacionó con dosis más altas de diuréticos y menor adherencia al tratamiento. Ambas complicaciones se asociaron de manera consistente con puntuaciones reducidas de calidad de vida y una carga física y emocional significativa. Las limitaciones de la evidencia incluyeron tamaños de muestra pequeños, definiciones y medidas de desenlace heterogéneas, y un seguimiento longitudinal limitado. En general, las complicaciones urológicas son comunes, clínicamente relevantes y con frecuencia subestimadas en la insuficiencia cardíaca avanzada. Estos hallazgos respaldan la integración rutinaria del cribado, asesoramiento y manejo específicos en la atención integral de la insuficiencia cardíaca, y destacan la necesidad de investigaciones prospectivas y estandarizadas.

1 April 2026 in Journal of Applied Hematology
Verified
Journal Article
Open access
CCCarlos Camargo
Carlos Camargo
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
YSYeimy Carolina Chaparro Sandoval
Yeimy Carolina Chaparro Sandoval
WGW. G. Galvis
W. G. Galvis
DADanniel Steven Jaramillo Agudelo
Danniel Steven Jaramillo Agudelo
GRGloria Ibis Tirado Romero
Gloria Ibis Tirado Romero
The therapeutic landscape for relapsed or refractory multiple myeloma (RRMM) has evolved with the introduction of B-cell maturation antigen (BCMA)-directed agents and novel triplet combinations; however, robust comparative evidence in lenalidomide-refractory patients with early relapse remains limited. We conducted a systematic review and network meta-analysis (NMA) of phase 3 randomized controlled trials (RCTs) comparing BCMA-targeted therapies with standard regimens in adults with RRMM after 1-3 prior lines. MEDLINE, Embase, CENTRAL, and Web of Science were searched from inception through December 2025. The primary endpoint was progression-free survival (PFS), which was quantitatively synthesized using NMA; overall survival (OS), minimal residual disease (MRD) negativity, and grade ≥3 adverse events were summarized descriptively. Ten phase 3 RCTs met the inclusion criteria. Experimental regimens consistently improved PFS compared with control arms, with hazard ratios ranging from 0.31 to 0.70 across trials. Within the connected network, anti-CD38-based triplets demonstrated the most favorable PFS estimates. Although BCMA-directed therapies showed superior efficacy in direct comparisons, including deeper responses and higher MRD negativity rates, limited network connectivity precluded robust indirect comparisons across therapeutic classes. OS data were heterogeneous and frequently immature, and safety outcomes were not quantitatively synthesized. Multiple therapeutic strategies improve PFS in lenalidomide-refractory RRMM during early relapse. Anti-CD38-based triplets remain a cornerstone of care, while BCMA-directed therapies represent a promising alternative. However, structural limitations of the evidence network warrant cautious interpretation.